BCL2 and MMP9 have been found to play significant roles in tumor immunity and may serve as potential novel biomarkers and therapeutic targets for immunotherapy of clear cell renal cell carcinoma (ccRCC) [46,47]. Here, BCL2 is linked to nonpapillary renal cell carcinoma.